Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President, Representative Director, Gyo Sagara; “ONO”) announced today that it has started clinical studies to investigate a proteinase inhibitor, Foipan® (generic name: camostat mesilate) Tablets (“Foipan”) for a novel coronavirus infection (COVID-19).